Cytokinetics CYTK · NASDAQ
$62.65 +1.13% (+$0.70)
Summary
16 / 100 · Bulios Score
What speaks for it
- Analysts expect revenue to grow by 72% this fiscal year.
- The price moves less than the market (beta 0.36).
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 2.4% a year over the last 3 years.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 9.5% a year over 5 years. Over the last 3 years it fell by 2.4% a year. For the next fiscal year analysts expect revenue to grow by 72%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $894.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 34
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $112.5 is 80% above today's price. 97% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Collaboration Revenues 100%
By region
- CHINA 100%
Collaboration Revenues brings in 100% of revenue.
Segments in detail